DrugA,DrugB,Interaction
Abciximab,Dabigatran,The risk or severity of bleeding can be increased when Abciximab is combined with Dabigatran.
Aceclofenac,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Dabigatran.
Acemetacin,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Acemetacin.
Acenocoumarol,Dabigatran,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dabigatran.
Acetylsalicylic acid,Dabigatran,Acetylsalicylic acid may increase the anticoagulant activities of Dabigatran.
Albutrepenonacog alfa,Dabigatran,The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dabigatran.
Alclofenac,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Dabigatran.
Aldesleukin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Aldesleukin.
Alemtuzumab,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Alemtuzumab.
Alteplase,Dabigatran,The risk or severity of bleeding can be increased when Alteplase is combined with Dabigatran.
Altretamine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Altretamine.
Aminophenazone,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Dabigatran.
Aminosalicylic acid,Dabigatran,The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dabigatran.
Amsacrine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Amsacrine.
Anagrelide,Dabigatran,The risk or severity of bleeding can be increased when Anagrelide is combined with Dabigatran.
Ancrod,Dabigatran,The risk or severity of bleeding can be increased when Ancrod is combined with Dabigatran.
Andexanet alfa,Dabigatran,The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Dabigatran.
Anistreplase,Dabigatran,The risk or severity of bleeding can be increased when Anistreplase is combined with Dabigatran.
Anti-inhibitor coagulant complex,Dabigatran,The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Dabigatran.
"Antihemophilic factor (recombinant), PEGylated",Dabigatran,"The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Dabigatran."
Antihemophilic factor human,Dabigatran,The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dabigatran.
"Antihemophilic factor, human recombinant",Dabigatran,"The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dabigatran."
Antipyrine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Dabigatran.
Antithrombin Alfa,Dabigatran,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dabigatran.
Antithrombin III human,Dabigatran,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Dabigatran.
Antrafenine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Dabigatran.
Apixaban,Dabigatran,Apixaban may increase the anticoagulant activities of Dabigatran.
Ardeparin,Dabigatran,The risk or severity of bleeding can be increased when Ardeparin is combined with Dabigatran.
Argatroban,Dabigatran,The risk or severity of bleeding can be increased when Argatroban is combined with Dabigatran.
Arsenic trioxide,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Arsenic trioxide.
Azacitidine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Azacitidine.
Azficel-T,Dabigatran,The risk or severity of adverse effects can be increased when Dabigatran is combined with Azficel-T.
Azithromycin,Dabigatran,The risk or severity of adverse effects can be increased when Azithromycin is combined with Dabigatran.
Balsalazide,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Dabigatran.
Belinostat,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Belinostat.
Bemiparin,Dabigatran,The risk or severity of bleeding can be increased when Bemiparin is combined with Dabigatran.
Bendamustine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Bendamustine.
Bendroflumethiazide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Bendroflumethiazide.
Benorilate,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Dabigatran.
Benoxaprofen,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Dabigatran.
Benzthiazide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Benzthiazide.
Benzydamine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Dabigatran.
Beroctocog alfa,Dabigatran,The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Dabigatran.
Betrixaban,Dabigatran,The risk or severity of bleeding can be increased when Betrixaban is combined with Dabigatran.
Bexarotene,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Bexarotene.
Bismuth subsalicylate,Dabigatran,The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Dabigatran.
Bivalirudin,Dabigatran,The risk or severity of bleeding can be increased when Bivalirudin is combined with Dabigatran.
Blinatumomab,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Blinatumomab.
Bortezomib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Bortezomib.
Bosutinib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Bosutinib.
Bumadizone,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Dabigatran.
Busulfan,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Busulfan.
Cabazitaxel,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Cabazitaxel.
Calcium acetate,Dabigatran,The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Dabigatran.
Calcium carbonate,Dabigatran,The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Dabigatran.
Calcium chloride,Dabigatran,The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Dabigatran.
Calcium citrate,Dabigatran,The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Dabigatran.
Calcium gluconate,Dabigatran,The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Dabigatran.
Calcium Phosphate,Dabigatran,The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Dabigatran.
Calcium threonate,Dabigatran,The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Dabigatran.
Cangrelor,Dabigatran,The risk or severity of bleeding can be increased when Cangrelor is combined with Dabigatran.
Capecitabine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Capecitabine.
Caplacizumab,Dabigatran,The risk or severity of bleeding can be increased when Caplacizumab is combined with Dabigatran.
Carbamazepine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Carbamazepine.
Carbimazole,Dabigatran,Carbimazole may increase the anticoagulant activities of Dabigatran.
Carboplatin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Carboplatin.
Carfilzomib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Carfilzomib.
Carmustine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Carmustine.
Carprofen,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Dabigatran.
Catridecacog,Dabigatran,The therapeutic efficacy of Catridecacog can be decreased when used in combination with Dabigatran.
Cefaclor,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefaclor.
Cefadroxil,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefadroxil.
Cefalotin,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefalotin.
Cefamandole,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefamandole.
Cefamandole nafate,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefamandole nafate.
Cefapirin,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefapirin.
Cefazolin,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefazolin.
Cefdinir,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefdinir.
Cefditoren,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefditoren.
Cefepime,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefepime.
Cefixime,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefixime.
Cefmenoxime,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefmenoxime.
Cefmetazole,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefmetazole.
Cefonicid,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefonicid.
Cefoperazone,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefoperazone.
Ceforanide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ceforanide.
Cefotaxime,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefotaxime.
Cefotetan,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefotetan.
Cefotiam,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefotiam.
Cefoxitin,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefoxitin.
Cefpiramide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefpiramide.
Cefpirome,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefpirome.
Cefpodoxime,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefpodoxime.
Cefprozil,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefprozil.
Cefradine,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefradine.
Ceftaroline fosamil,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ceftaroline fosamil.
Ceftazidime,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ceftazidime.
Ceftibuten,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ceftibuten.
Ceftizoxime,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ceftizoxime.
Ceftobiprole,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ceftobiprole.
Ceftolozane,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ceftolozane.
Ceftriaxone,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ceftriaxone.
Cefuroxime,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefuroxime.
Celecoxib,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Dabigatran.
Cephalexin,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cephalexin.
Cephaloglycin,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cephaloglycin.
Chenodeoxycholic acid,Dabigatran,The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Chenodeoxycholic acid.
Chlorambucil,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Chlorambucil.
Chloramphenicol,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Chloramphenicol.
Chlorothiazide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Chlorothiazide.
Cholic Acid,Dabigatran,The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Cholic Acid.
Choline magnesium trisalicylate,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Dabigatran.
Choline salicylate,Dabigatran,The risk or severity of bleeding can be increased when Choline salicylate is combined with Dabigatran.
Cilostazol,Dabigatran,The risk or severity of bleeding can be increased when Cilostazol is combined with Dabigatran.
Cisplatin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Cisplatin.
Citalopram,Dabigatran,The risk or severity of hemorrhage can be increased when Citalopram is combined with Dabigatran.
Cladribine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Cladribine.
Clofarabine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Clofarabine.
Clopidogrel,Dabigatran,The risk or severity of bleeding can be increased when Clopidogrel is combined with Dabigatran.
Coagulation Factor IX (Recombinant),Dabigatran,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dabigatran.
Coagulation Factor IX Human,Dabigatran,The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Dabigatran.
Coagulation factor VII human,Dabigatran,The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Dabigatran.
Coagulation factor VIIa Recombinant Human,Dabigatran,The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dabigatran.
Coagulation factor X human,Dabigatran,The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dabigatran.
Collagenase clostridium histolyticum,Dabigatran,The risk or severity of adverse effects can be increased when Dabigatran is combined with Collagenase clostridium histolyticum.
Conjugated estrogens,Dabigatran,Conjugated estrogens may decrease the anticoagulant activities of Dabigatran.
Cyclopenthiazide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cyclopenthiazide.
Cyclophosphamide,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Cyclophosphamide.
Cyclothiazide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cyclothiazide.
Cyproterone acetate,Dabigatran,The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Dabigatran.
Cytarabine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Cytarabine.
Dabigatran etexilate,Dabigatran,Dabigatran etexilate may increase the anticoagulant activities of Dabigatran.
Dacarbazine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Dacarbazine.
Dactinomycin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Dactinomycin.
Dalteparin,Dabigatran,The risk or severity of bleeding can be increased when Dalteparin is combined with Dabigatran.
Damoctocog alfa pegol,Dabigatran,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Dabigatran.
Danaparoid,Dabigatran,The risk or severity of bleeding can be increased when Danaparoid is combined with Dabigatran.
Dasatinib,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dabigatran.
Daunorubicin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Daunorubicin.
Decitabine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Decitabine.
Deferasirox,Dabigatran,The risk or severity of gastrointestinal bleeding can be increased when Dabigatran is combined with Deferasirox.
Defibrotide,Dabigatran,The risk or severity of bleeding can be increased when Defibrotide is combined with Dabigatran.
Dehydrocholic acid,Dabigatran,The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Dehydrocholic acid.
Deoxycholic acid,Dabigatran,The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Deoxycholic acid.
Desirudin,Dabigatran,The risk or severity of bleeding can be increased when Desirudin is combined with Dabigatran.
Desogestrel,Dabigatran,The risk or severity of adverse effects can be increased when Desogestrel is combined with Dabigatran.
Desvenlafaxine,Dabigatran,The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Dabigatran.
Dexketoprofen,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Dabigatran.
Dexrazoxane,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Dexrazoxane.
Dextran,Dabigatran,The risk or severity of bleeding can be increased when Dextran is combined with Dabigatran.
Diclofenac,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Dabigatran.
Dicoumarol,Dabigatran,The risk or severity of bleeding can be increased when Dicoumarol is combined with Dabigatran.
Dienogest,Dabigatran,The risk or severity of adverse effects can be increased when Dienogest is combined with Dabigatran.
Diethylstilbestrol,Dabigatran,Diethylstilbestrol may decrease the anticoagulant activities of Dabigatran.
Diflunisal,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Dabigatran.
Dinutuximab,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Dinutuximab.
Dipyridamole,Dabigatran,The risk or severity of bleeding can be increased when Dipyridamole is combined with Dabigatran.
Docetaxel,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Docetaxel.
Doxorubicin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Doxorubicin.
Doxycycline,Dabigatran,The risk or severity of bleeding can be increased when Doxycycline is combined with Dabigatran.
Drospirenone,Dabigatran,The risk or severity of adverse effects can be increased when Drospirenone is combined with Dabigatran.
Drostanolone propionate,Dabigatran,Drostanolone propionate may increase the anticoagulant activities of Dabigatran.
Drotrecogin alfa,Dabigatran,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dabigatran.
Duloxetine,Dabigatran,The risk or severity of hemorrhage can be increased when Duloxetine is combined with Dabigatran.
Dydrogesterone,Dabigatran,Dydrogesterone may decrease the anticoagulant activities of Dabigatran.
Edetate calcium disodium anhydrous,Dabigatran,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Dabigatran.
Edetic acid,Dabigatran,The risk or severity of bleeding can be increased when Edetic acid is combined with Dabigatran.
Edoxaban,Dabigatran,The risk or severity of bleeding can be increased when Edoxaban is combined with Dabigatran.
Eftrenonacog alfa,Dabigatran,The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Dabigatran.
Emicizumab,Dabigatran,The therapeutic efficacy of Emicizumab can be decreased when used in combination with Dabigatran.
Enoxaparin,Dabigatran,The risk or severity of bleeding can be increased when Enoxaparin is combined with Dabigatran.
Epirubicin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Epirubicin.
Epoprostenol,Dabigatran,The risk or severity of bleeding can be increased when Epoprostenol is combined with Dabigatran.
Eptifibatide,Dabigatran,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dabigatran.
Eribulin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Eribulin.
Erythromycin,Dabigatran,The risk or severity of bleeding can be increased when Erythromycin is combined with Dabigatran.
Escitalopram,Dabigatran,The risk or severity of bleeding can be increased when Escitalopram is combined with Dabigatran.
Esterified estrogens,Dabigatran,Esterified estrogens may decrease the anticoagulant activities of Dabigatran.
Estetrol,Dabigatran,The risk or severity of adverse effects can be increased when Estetrol is combined with Dabigatran.
Estradiol,Dabigatran,The risk or severity of adverse effects can be increased when Estradiol is combined with Dabigatran.
Estradiol acetate,Dabigatran,Estradiol acetate may decrease the anticoagulant activities of Dabigatran.
Estradiol benzoate,Dabigatran,Estradiol benzoate may decrease the anticoagulant activities of Dabigatran.
Estradiol cypionate,Dabigatran,Estradiol cypionate may decrease the anticoagulant activities of Dabigatran.
Estradiol valerate,Dabigatran,Estradiol valerate may decrease the anticoagulant activities of Dabigatran.
Estriol,Dabigatran,Estriol may decrease the anticoagulant activities of Dabigatran.
Estrone sulfate,Dabigatran,Estrone sulfate may decrease the anticoagulant activities of Dabigatran.
Ethinylestradiol,Dabigatran,The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Dabigatran.
Ethynodiol diacetate,Dabigatran,The risk or severity of adverse effects can be increased when Ethynodiol diacetate is combined with Dabigatran.
Etodolac,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Dabigatran.
Etonogestrel,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Etonogestrel.
Etoposide,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Etoposide.
Etoricoxib,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Dabigatran.
Everolimus,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Everolimus.
Factor IX Complex (Human),Dabigatran,The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Dabigatran.
Factor XIII (human),Dabigatran,The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dabigatran.
Fenbufen,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Dabigatran.
Fenoprofen,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Dabigatran.
Fibrinogen human,Dabigatran,The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Dabigatran.
Floctafenine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Dabigatran.
Floxuridine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Floxuridine.
Flucytosine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Flucytosine.
Fludarabine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Fludarabine.
Fluindione,Dabigatran,The risk or severity of bleeding can be increased when Fluindione is combined with Dabigatran.
Fluorouracil,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Fluorouracil.
Fluoxetine,Dabigatran,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dabigatran.
Flurbiprofen,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Dabigatran.
Fluvoxamine,Dabigatran,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Dabigatran.
Fondaparinux,Dabigatran,The risk or severity of bleeding can be increased when Fondaparinux is combined with Dabigatran.
Gemcitabine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Gemcitabine.
Gemtuzumab ozogamicin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Gemtuzumab ozogamicin.
Gestrinone,Dabigatran,The risk or severity of adverse effects can be increased when Gestrinone is combined with Dabigatran.
Ginkgo biloba,Dabigatran,Ginkgo biloba may increase the anticoagulant activities of Dabigatran.
Glycol salicylate,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Dabigatran.
Hemin,Dabigatran,Hemin may increase the anticoagulant activities of Dabigatran.
Heparin,Dabigatran,The risk or severity of bleeding can be increased when Heparin is combined with Dabigatran.
Hydrochlorothiazide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Hydrochlorothiazide.
Hydroflumethiazide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproate,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Hydroxyprogesterone caproate.
Hydroxyurea,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Hydroxyurea.
Ibritumomab tiuxetan,Dabigatran,The risk or severity of adverse effects can be increased when Dabigatran is combined with Ibritumomab tiuxetan.
Ibrutinib,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dabigatran.
Icosapent,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Dabigatran.
Icosapent ethyl,Dabigatran,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dabigatran.
Idarubicin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Idarubicin.
Ifosfamide,Dabigatran,The risk or severity of bleeding can be increased when Ifosfamide is combined with Dabigatran.
Iloprost,Dabigatran,The risk or severity of bleeding can be increased when Iloprost is combined with Dabigatran.
Imatinib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Imatinib.
Indomethacin,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Dabigatran.
Interferon alfa-2a,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-2a.
Interferon alfa-2b,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-2b.
Interferon alfa-n1,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-n1.
Interferon alfa-n3,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-n3.
Interferon alfacon-1,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfacon-1.
Interferon beta-1b,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon beta-1b.
Interferon gamma-1b,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon gamma-1b.
Irinotecan,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Irinotecan.
Isocarboxazid,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Dabigatran.
Isoxicam,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Dabigatran.
Ixabepilone,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Ixabepilone.
Ketoprofen,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Dabigatran.
Ketorolac,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Dabigatran.
Latamoxef,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Latamoxef.
Lenalidomide,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Lenalidomide.
Lepirudin,Dabigatran,The risk or severity of bleeding can be increased when Lepirudin is combined with Dabigatran.
Levocarnitine,Dabigatran,The therapeutic efficacy of Dabigatran can be increased when used in combination with Levocarnitine.
Levomilnacipran,Dabigatran,The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dabigatran.
Levonorgestrel,Dabigatran,The risk or severity of adverse effects can be increased when Levonorgestrel is combined with Dabigatran.
Linezolid,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Dabigatran.
Lomustine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Lomustine.
Loracarbef,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Loracarbef.
Lornoxicam,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Dabigatran.
Loxoprofen,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Dabigatran.
Lumiracoxib,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Dabigatran.
Lynestrenol,Dabigatran,The risk or severity of adverse effects can be increased when Lynestrenol is combined with Dabigatran.
Mechlorethamine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Mechlorethamine.
Meclofenamic acid,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Dabigatran.
Medrogestone,Dabigatran,Medrogestone may decrease the anticoagulant activities of Dabigatran.
Medroxyprogesterone acetate,Dabigatran,The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Dabigatran.
Mefenamic acid,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Dabigatran.
Megestrol acetate,Dabigatran,The risk or severity of adverse effects can be increased when Megestrol acetate is combined with Dabigatran.
Meloxicam,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dabigatran.
Melphalan,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Melphalan.
Menthyl salicylate,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Menthyl salicylate is combined with Dabigatran.
Mercaptopurine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Mercaptopurine.
Mesalazine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dabigatran.
Mestranol,Dabigatran,Mestranol may decrease the anticoagulant activities of Dabigatran.
Metamizole,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Dabigatran.
Methimazole,Dabigatran,Methimazole may increase the anticoagulant activities of Dabigatran.
Methotrexate,Dabigatran,The excretion of Methotrexate can be decreased when combined with Dabigatran.
Methyl salicylate,Dabigatran,The risk or severity of bleeding can be increased when Methyl salicylate is combined with Dabigatran.
Methylene blue,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Dabigatran.
Mifepristone,Dabigatran,The risk or severity of adverse effects can be increased when Mifepristone is combined with Dabigatran.
Milnacipran,Dabigatran,The risk or severity of hemorrhage can be increased when Milnacipran is combined with Dabigatran.
Minaprine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Dabigatran.
Mitomycin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Mitomycin.
Mitoxantrone,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Mitoxantrone.
Moclobemide,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Dabigatran.
Moroctocog alfa,Dabigatran,The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Dabigatran.
Nabumetone,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Dabigatran.
Nadroparin,Dabigatran,The risk or severity of bleeding can be increased when Nadroparin is combined with Dabigatran.
Naproxen,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dabigatran.
Nefazodone,Dabigatran,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Dabigatran.
Nelarabine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Nelarabine.
Nialamide,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Dabigatran.
Nilotinib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Nilotinib.
Nimesulide,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Dabigatran.
Nintedanib,Dabigatran,The risk or severity of bleeding can be increased when Nintedanib is combined with Dabigatran.
Nomegestrol,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Nomegestrol.
Nomegestrol acetate,Dabigatran,The risk or severity of adverse effects can be increased when Nomegestrol acetate is combined with Dabigatran.
Nonacog beta pegol,Dabigatran,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Dabigatran.
Norelgestromin,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Norelgestromin.
Norethisterone,Dabigatran,The risk or severity of adverse effects can be increased when Norethisterone is combined with Dabigatran.
Norethynodrel,Dabigatran,The risk or severity of adverse effects can be increased when Norethynodrel is combined with Dabigatran.
Norgestimate,Dabigatran,The risk or severity of adverse effects can be increased when Norgestimate is combined with Dabigatran.
Norgestrel,Dabigatran,The risk or severity of adverse effects can be increased when Norgestrel is combined with Dabigatran.
Obeticholic acid,Dabigatran,The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Obeticholic acid.
Obinutuzumab,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Obinutuzumab.
Olaparib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Olaparib.
Olsalazine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Dabigatran.
Omacetaxine mepesuccinate,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Omacetaxine mepesuccinate.
Omega-3 fatty acids,Dabigatran,Omega-3 fatty acids may increase the anticoagulant activities of Dabigatran.
Omega-3-acid ethyl esters,Dabigatran,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dabigatran.
Omega-3-carboxylic acids,Dabigatran,The therapeutic efficacy of Dabigatran can be increased when used in combination with Omega-3-carboxylic acids.
Oxaliplatin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Oxaliplatin.
Oxaprozin,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Dabigatran.
Oxyphenbutazone,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Dabigatran.
Paclitaxel,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Paclitaxel.
Palbociclib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Palbociclib.
Pantothenic acid,Dabigatran,The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Dabigatran.
Parecoxib,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Dabigatran.
Pargyline,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Dabigatran.
Parnaparin,Dabigatran,The risk or severity of bleeding can be increased when Parnaparin is combined with Dabigatran.
Paroxetine,Dabigatran,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dabigatran.
Peginterferon alfa-2a,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Peginterferon alfa-2a.
Peginterferon alfa-2b,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Peginterferon alfa-2b.
Peginterferon beta-1a,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Peginterferon beta-1a.
Pemetrexed,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Pemetrexed.
Penicillamine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Penicillamine.
Pentosan polysulfate,Dabigatran,Pentosan polysulfate may increase the anticoagulant activities of Dabigatran.
Pentostatin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Pentostatin.
Pentoxifylline,Dabigatran,The therapeutic efficacy of Dabigatran can be increased when used in combination with Pentoxifylline.
Phenelzine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Dabigatran.
Phenindione,Dabigatran,The risk or severity of bleeding can be increased when Phenindione is combined with Dabigatran.
Phenprocoumon,Dabigatran,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Dabigatran.
Phenyl aminosalicylate,Dabigatran,The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Dabigatran.
Phenylalanine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Phenylalanine.
Phenylbutazone,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Dabigatran.
Piroxicam,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Dabigatran.
Polyestradiol phosphate,Dabigatran,Polyestradiol phosphate may decrease the anticoagulant activities of Dabigatran.
Polythiazide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Polythiazide.
Pomalidomide,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Pomalidomide.
Ponatinib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Ponatinib.
Potassium citrate,Dabigatran,The risk or severity of bleeding can be increased when Potassium citrate is combined with Dabigatran.
Potassium Iodide,Dabigatran,Potassium Iodide may increase the anticoagulant activities of Dabigatran.
Potassium perchlorate,Dabigatran,Potassium perchlorate may increase the anticoagulant activities of Dabigatran.
Prasugrel,Dabigatran,The risk or severity of bleeding can be increased when Prasugrel is combined with Dabigatran.
Procaine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Dabigatran.
Procarbazine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Dabigatran.
Progesterone,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Progesterone.
Propylthiouracil,Dabigatran,Propylthiouracil may increase the anticoagulant activities of Dabigatran.
Protein C,Dabigatran,The risk or severity of bleeding can be increased when Protein C is combined with Dabigatran.
Protein S human,Dabigatran,The risk or severity of bleeding can be increased when Protein S human is combined with Dabigatran.
Prothrombin,Dabigatran,The therapeutic efficacy of Prothrombin can be decreased when used in combination with Dabigatran.
Quinestrol,Dabigatran,Quinestrol may decrease the anticoagulant activities of Dabigatran.
Quinidine,Dabigatran,The therapeutic efficacy of Dabigatran can be increased when used in combination with Quinidine.
Quinine,Dabigatran,The therapeutic efficacy of Dabigatran can be increased when used in combination with Quinine.
Raltitrexed,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Raltitrexed.
Rasagiline,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Dabigatran.
Reteplase,Dabigatran,The risk or severity of bleeding can be increased when Reteplase is combined with Dabigatran.
Reviparin,Dabigatran,The risk or severity of bleeding can be increased when Reviparin is combined with Dabigatran.
Rituximab,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Rituximab.
Rivaroxaban,Dabigatran,Dabigatran may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Dabigatran.
Ruxolitinib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Ruxolitinib.
Safinamide,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Dabigatran.
Salicylamide,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Dabigatran.
Salicylic acid,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Dabigatran.
Salsalate,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Dabigatran.
Selegiline,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Dabigatran.
Sertraline,Dabigatran,The risk or severity of bleeding can be increased when Sertraline is combined with Dabigatran.
Sevoflurane,Dabigatran,The risk or severity of bleeding can be increased when Sevoflurane is combined with Dabigatran.
Sibutramine,Dabigatran,The risk or severity of hemorrhage can be increased when Sibutramine is combined with Dabigatran.
Sildenafil,Dabigatran,The risk or severity of hemorrhage can be increased when Dabigatran is combined with Sildenafil.
Sirolimus,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Sirolimus.
Sodium citrate,Dabigatran,The risk or severity of bleeding can be increased when Sodium citrate is combined with Dabigatran.
Sorafenib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Sorafenib.
Streptokinase,Dabigatran,The risk or severity of bleeding can be increased when Streptokinase is combined with Dabigatran.
Streptozocin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Streptozocin.
Sugammadex,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Sugammadex.
Sulfasalazine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Dabigatran.
Sulfinpyrazone,Dabigatran,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dabigatran.
Sulindac,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dabigatran.
Sulodexide,Dabigatran,The risk or severity of bleeding can be increased when Sulodexide is combined with Dabigatran.
Susoctocog alfa,Dabigatran,The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Dabigatran.
"Synthetic Conjugated Estrogens, A",Dabigatran,"Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dabigatran."
"Synthetic Conjugated Estrogens, B",Dabigatran,"Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dabigatran."
Tacrolimus,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Tacrolimus.
Tamoxifen,Dabigatran,The risk or severity of bleeding can be increased when Tamoxifen is combined with Dabigatran.
Taurocholic acid,Dabigatran,The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Taurocholic acid.
Tazobactam,Dabigatran,The risk or severity of bleeding can be increased when Tazobactam is combined with Dabigatran.
Tedizolid phosphate,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Tedizolid phosphate.
Temozolomide,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Temozolomide.
Temsirolimus,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Temsirolimus.
Tenecteplase,Dabigatran,The risk or severity of bleeding can be increased when Tenecteplase is combined with Dabigatran.
Teniposide,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Teniposide.
Tenoxicam,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Dabigatran.
Testosterone,Dabigatran,Testosterone may increase the anticoagulant activities of Dabigatran.
Testosterone cypionate,Dabigatran,Testosterone cypionate may increase the anticoagulant activities of Dabigatran.
Testosterone enantate benzilic acid hydrazone,Dabigatran,Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Dabigatran.
Testosterone enanthate,Dabigatran,Testosterone enanthate may increase the anticoagulant activities of Dabigatran.
Testosterone propionate,Dabigatran,Testosterone propionate may increase the anticoagulant activities of Dabigatran.
Testosterone undecanoate,Dabigatran,Testosterone undecanoate may increase the anticoagulant activities of Dabigatran.
Thalidomide,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Thalidomide.
Thiotepa,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Thiotepa.
Tiaprofenic acid,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Dabigatran.
Tibolone,Dabigatran,Tibolone may increase the anticoagulant activities of Dabigatran.
Ticagrelor,Dabigatran,The risk or severity of bleeding can be increased when Ticagrelor is combined with Dabigatran.
Ticlopidine,Dabigatran,The risk or severity of bleeding can be increased when Ticlopidine is combined with Dabigatran.
Tinzaparin,Dabigatran,The risk or severity of bleeding can be increased when Tinzaparin is combined with Dabigatran.
Tioguanine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Tioguanine.
Tipranavir,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dabigatran.
Tirofiban,Dabigatran,The risk or severity of bleeding can be increased when Tirofiban is combined with Dabigatran.
Tofacitinib,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Tofacitinib.
Tolfenamic acid,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Dabigatran.
Tolmetin,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Dabigatran.
Topotecan,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Topotecan.
Toremifene,Dabigatran,The risk or severity of bleeding can be increased when Toremifene is combined with Dabigatran.
Tositumomab,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Tositumomab.
Trabectedin,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Trabectedin.
Tranylcypromine,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Dabigatran.
Trastuzumab emtansine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Trastuzumab emtansine.
Trazodone,Dabigatran,The risk or severity of bleeding can be increased when Trazodone is combined with Dabigatran.
Treprostinil,Dabigatran,The risk or severity of bleeding can be increased when Treprostinil is combined with Dabigatran.
Triamcinolone,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Triamcinolone.
Trichlormethiazide,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Trichlormethiazide.
Triflusal,Dabigatran,The risk or severity of bleeding can be increased when Triflusal is combined with Dabigatran.
Trolamine salicylate,Dabigatran,The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Dabigatran.
Turoctocog alfa,Dabigatran,The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Dabigatran.
Turoctocog alfa pegol,Dabigatran,The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Dabigatran.
Ulipristal,Dabigatran,The therapeutic efficacy of Dabigatran can be decreased when used in combination with Ulipristal.
Urokinase,Dabigatran,Urokinase may increase the anticoagulant activities of Dabigatran.
Ursodeoxycholic acid,Dabigatran,The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Ursodeoxycholic acid.
Valdecoxib,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Dabigatran.
Venlafaxine,Dabigatran,Venlafaxine may increase the antiplatelet activities of Dabigatran.
Vinblastine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Vinblastine.
Vindesine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Vindesine.
Vinorelbine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Vinorelbine.
Vitamin E,Dabigatran,Vitamin E may increase the anticoagulant activities of Dabigatran.
Von Willebrand factor human,Dabigatran,The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dabigatran.
Vorapaxar,Dabigatran,The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Dabigatran.
Vorinostat,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Vorinostat.
Warfarin,Dabigatran,The risk or severity of bleeding can be increased when Warfarin is combined with Dabigatran.
Ximelagatran,Dabigatran,The risk or severity of bleeding can be increased when Ximelagatran is combined with Dabigatran.
Zidovudine,Dabigatran,The risk or severity of bleeding can be increased when Dabigatran is combined with Zidovudine.
Zimelidine,Dabigatran,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Dabigatran.
Abacavir,Daptomycin,Daptomycin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abemaciclib,Daptomycin,The serum concentration of Abemaciclib can be increased when it is combined with Daptomycin.
Aceclofenac,Daptomycin,Aceclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Acemetacin,Daptomycin,Acemetacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Acenocoumarol,Daptomycin,The risk or severity of bleeding can be increased when Daptomycin is combined with Acenocoumarol.
Acetaminophen,Daptomycin,Daptomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetazolamide,Daptomycin,Acetazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid,Daptomycin,Acetylsalicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Acipimox,Daptomycin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Acipimox."
Aclidinium,Daptomycin,Daptomycin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine,Daptomycin,Daptomycin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir,Daptomycin,Acyclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Adefovir dipivoxil,Daptomycin,Adefovir dipivoxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Afatinib,Daptomycin,The serum concentration of Daptomycin can be increased when it is combined with Afatinib.
Albutrepenonacog alfa,Daptomycin,Daptomycin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac,Daptomycin,Alclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Aldesleukin,Daptomycin,Aldesleukin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Alendronic acid,Daptomycin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid."
Allopurinol,Daptomycin,Daptomycin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Almasilate,Daptomycin,Daptomycin may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan,Daptomycin,Daptomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Alogliptin,Daptomycin,Daptomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Alprazolam,Daptomycin,Daptomycin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Amantadine,Daptomycin,Daptomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.
Ambrisentan,Daptomycin,The serum concentration of Ambrisentan can be increased when it is combined with Daptomycin.
Amikacin,Daptomycin,Daptomycin may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride,Daptomycin,Amiloride may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Aminophenazone,Daptomycin,Aminophenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Amiodarone,Daptomycin,The serum concentration of Daptomycin can be increased when it is combined with Amiodarone.
Amitriptyline,Daptomycin,Daptomycin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
Ammonium chloride,Daptomycin,Daptomycin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Amoxicillin,Daptomycin,Daptomycin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amphetamine,Daptomycin,Daptomycin may decrease the excretion rate of Amphetamine which could result in a higher serum level.
Amphotericin B,Daptomycin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Amphotericin B."
Ampicillin,Daptomycin,Daptomycin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Amrinone,Daptomycin,Daptomycin may decrease the excretion rate of Amrinone which could result in a higher serum level.
Ancestim,Daptomycin,Daptomycin may decrease the excretion rate of Ancestim which could result in a higher serum level.
"Antihemophilic factor (recombinant), PEGylated",Daptomycin,"Daptomycin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level."
Antipyrine,Daptomycin,Antipyrine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Antithrombin III human,Daptomycin,Daptomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antrafenine,Daptomycin,Antrafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Apalutamide,Daptomycin,The serum concentration of Daptomycin can be decreased when it is combined with Apalutamide.
Apixaban,Daptomycin,The serum concentration of Apixaban can be increased when it is combined with Daptomycin.
Apremilast,Daptomycin,Daptomycin may decrease the excretion rate of Apremilast which could result in a higher serum level.
Arformoterol,Daptomycin,Daptomycin may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Arsenic trioxide,Daptomycin,The serum concentration of Daptomycin can be increased when it is combined with Arsenic trioxide.
Asunaprevir,Daptomycin,The serum concentration of Daptomycin can be increased when it is combined with Asunaprevir.
Atazanavir,Daptomycin,Atazanavir may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Atomoxetine,Daptomycin,Daptomycin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
Atorvastatin,Daptomycin,The risk or severity of myopathy can be increased when Atorvastatin is combined with Daptomycin.
Auranofin,Daptomycin,Daptomycin may decrease the excretion rate of Auranofin which could result in a higher serum level.
Aurothioglucose,Daptomycin,Daptomycin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Avanafil,Daptomycin,The serum concentration of Avanafil can be increased when it is combined with Daptomycin.
Avatrombopag,Daptomycin,The serum concentration of Avatrombopag can be increased when it is combined with Daptomycin.
Axitinib,Daptomycin,The serum concentration of Axitinib can be increased when it is combined with Daptomycin.
Azacitidine,Daptomycin,Daptomycin may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Azathioprine,Daptomycin,Daptomycin may decrease the excretion rate of Azathioprine which could result in a higher serum level.
Azelaic acid,Daptomycin,Daptomycin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Aztreonam,Daptomycin,Daptomycin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Bacitracin,Daptomycin,Bacitracin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Baclofen,Daptomycin,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Baclofen."
Balsalazide,Daptomycin,Balsalazide may decrease the excretion rate of Daptomycin which could result in a higher serum level.
Baricitinib,Daptomycin,The serum concentration of Baricitinib can be increased when it is combined with Daptomycin.
BCG vaccine,Daptomycin,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Daptomycin.
Belantamab mafodotin,Daptomycin,The serum concentration of Belantamab mafodotin can be increased when it is combined with Daptomycin.
